Trial Profile
A Phase 2, Randomized, Open Label Study Evaluating the Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Subjects With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jan 2020
Price :
$35
*
At a glance
- Drugs Selonsertib (Primary) ; Simtuzumab (Primary)
- Indications Hepatic fibrosis; Non-alcoholic steatohepatitis
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 13 Nov 2018 Results validating a new quantitative blood test for assessing NASH severity, presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases.
- 13 Nov 2018 Results assessing the feasibility of using Deep-Learning Techniques to access Hepatic Fibrosis Directly from Magnetic Resonance Elastography Source Images (n=67) presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases
- 03 Oct 2018 Results assessing Longitudinal Correlations Between magnetic resonance elastography (MRE), MR imaging-estimated proton density fat fraction (MRI-PDFF ), and Liver Histology published in the Journal of Hepatology.